DDInter1340 DDInter1482
Originally approved by the FDA in 1989, omeprazole is a _proton-pump inhibitor_, used to treat gastric acid-related disorders. These disorders may include gastroesophageal reflux disease (GERD), peptic ulcer disease, and other diseases characterized by the oversecretion of gastric acid. This drug was the first clinical useful drug in its class, and its approval was followed by the formulation of many other proton pump inhibitor drugs. Omeprazole is generally effective and well-tolerated, promoting its popular use in children and adults [FDA label].
Developed by Achaogen biopharmaceuticals, plazomicin is a next-generation aminoglycoside synthetically derived from . The structure of plazomicin was established via appending hydroxylaminobutyric acid to at position 1 and 2-hydroxyethyl group at position 6' . It was designed to evade all clinically relevant aminoglycoside-modifying enzymes, which contribute to the main resistance mechanism for aminoglycoside therapy . However, acquired resistance of aminoglycosides may arise through over expression of efflux pumps and ribosomal modification by bacteria, which results from amino acid or rRNA sequence mutations . Like other aminoglycosides, plazomicin is ineffective against bacterial isolates that produce 16S rRNA methyltransferases [FDA Label]. Plazomicin mediates the antibacterial activity against pathogens including carbapenem-resistant (CRE) and extended-spectrum beta-lactamase (ESBL) producing _Enterobacteriaceae_. It mediates the antibacterial activity by binding to bacterial 30S ribosomal subunit and inhibiting protein synthesis [FDA Label]. On June 28th, 2018, plazomicin sulfate was approved by the FDA for use in adult patients for the treatment of complicated urinary tract infections (cUTI) including Pyelonephritis. It is marketed as Zemdri and is administered via once-daily intravenous infusion.
Omeprazole {u} (Compound) resembles {v} (Compound) Pantoprazole
Pantoprazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Plazomicin
Omeprazole {u} (Compound) resembles {v} (Compound) Rabeprazole
Rabeprazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Plazomicin
Omeprazole {u} (Compound) resembles {v} (Compound) Pantoprazole
Pantoprazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Acetylsalicylic acid
Acetylsalicylic acid {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Plazomicin
Omeprazole {u} (Compound) resembles {v} (Compound) Rabeprazole
Rabeprazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Acetylsalicylic acid
Acetylsalicylic acid {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Plazomicin
Omeprazole {u} (Compound) resembles {v} (Compound) Esomeprazole
Esomeprazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Acetylsalicylic acid
Acetylsalicylic acid {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Plazomicin
Omeprazole {u} (Compound) binds {v} (Gene) CYP2C18
CYP2C18 {u} (Gene) is bound by {v} (Compound) Lidocaine
Lidocaine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Plazomicin
Omeprazole {u} (Compound) resembles {v} (Compound) Pantoprazole
Pantoprazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Kanamycin
Kanamycin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Plazomicin
Omeprazole {u} (Compound) resembles {v} (Compound) Rabeprazole
Rabeprazole {u} (Compound) resembles {v} (Compound) Pantoprazole
Pantoprazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Plazomicin
Omeprazole {u} (Compound) binds {v} (Gene) CYP2C18
CYP2C18 {u} (Gene) is bound by {v} (Compound) Cyclophosphamide
Cyclophosphamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Plazomicin
Omeprazole {u} (Compound) resembles {v} (Compound) Rabeprazole
Rabeprazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Kanamycin
Kanamycin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Plazomicin
Omeprazole (Compound) resembles Pantoprazole (Compound) and Pantoprazole may cause a moderate interaction that could exacerbate diseases when taken with Plazomicin
Omeprazole (Compound) resembles Rabeprazole (Compound) and Rabeprazole may cause a moderate interaction that could exacerbate diseases when taken with Plazomicin
Omeprazole (Compound) resembles Pantoprazole (Compound) and Pantoprazole may cause a minor interaction that can limit clinical effects when taken with Acetylsalicylic acid and Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Plazomicin
Omeprazole (Compound) resembles Rabeprazole (Compound) and Rabeprazole may cause a minor interaction that can limit clinical effects when taken with Acetylsalicylic acid and Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Plazomicin
Omeprazole (Compound) resembles Esomeprazole (Compound) and Esomeprazole may cause a minor interaction that can limit clinical effects when taken with Acetylsalicylic acid and Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Plazomicin
Omeprazole (Compound) binds CYP2C18 (Gene) and CYP2C18 (Gene) is bound by Lidocaine (Compound) and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Plazomicin
Omeprazole (Compound) resembles Pantoprazole (Compound) and Pantoprazole may cause a moderate interaction that could exacerbate diseases when taken with Kanamycin and Kanamycin may cause a moderate interaction that could exacerbate diseases when taken with Plazomicin
Omeprazole (Compound) resembles Rabeprazole (Compound) and Rabeprazole (Compound) resembles Pantoprazole (Compound) and Pantoprazole may cause a moderate interaction that could exacerbate diseases when taken with Plazomicin
Omeprazole (Compound) binds CYP2C18 (Gene) and CYP2C18 (Gene) is bound by Cyclophosphamide (Compound) and Cyclophosphamide may cause a moderate interaction that could exacerbate diseases when taken with Plazomicin
Omeprazole (Compound) resembles Rabeprazole (Compound) and Rabeprazole may cause a moderate interaction that could exacerbate diseases when taken with Kanamycin and Kanamycin may cause a moderate interaction that could exacerbate diseases when taken with Plazomicin